Menu

Federal Science Funding Could Increase Under New Budget Deal

Congress has increased discretionary spending caps, making it possible that the budgets of US science agencies will rise this fiscal year.

Feb 12, 2018
Shawna Williams

ISTOCK, OPENMINDEDEThe budget deal signed into US law on Friday (February 9) increases the caps on nondefense discretionary spending—a category that includes science agencies such as the National Institutes of Health, the National Science Foundation, and NASA—by $143 billion (12.9 percent) in fiscal year 2018, and by $153 billion in 2019, reports the American Association for the Advancement of Science (AAAS). But how those funds will be allocated will not be determined until Congress passes an appropriations bill.

AAAS’s Matt Hourihan tells Science News that “Generally, research and development funding tends to track the discretionary budget pretty closely . . . most likely we're looking at a larger increase this year, and then a far more moderate increase next year. Within that context, agencies will fare better or worse based on their current popularity.”

In response to the news about the deal, which ended a very brief government shutdown, the American Chemical Society (ACS) released a statement that reads in part, “ACS is encouraged by the bipartisan budget deal that includes an increase in domestic spending over two years. ACS encourages Congress to invest heavily in scientific research and education, which are key elements of the U.S. innovation pipeline that drives job creation and economic growth.”

Defense spending caps also increased under Friday’s deal. The White House is expected to release a proposed budget today (February 12) that reflects the new funding limits. Such proposals from the president are not binding, but reflect the administration’s priorities, CNBC reports.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.